<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941018</url>
  </required_header>
  <id_info>
    <org_study_id>RX-10001-002</org_study_id>
    <nct_id>NCT00941018</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resolvyx Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Resolvyx Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine the safety, tolerability, pharmacodynamics and
      pharmacokinetics of RX-10001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability following single and multiple ascending oral doses as assessed by adverse events, vital signs, 12-lead ECG, clinical laboratory and physical exam.</measure>
    <time_frame>1 and 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pk and pharmacodynamics after single and multiple ascending doses</measure>
    <time_frame>1 and 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10001</intervention_name>
    <description>RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.</description>
    <arm_group_label>SAD cohort 1</arm_group_label>
    <arm_group_label>SAD cohort 2</arm_group_label>
    <arm_group_label>MAD cohort 1</arm_group_label>
    <arm_group_label>MAD cohort 2</arm_group_label>
    <arm_group_label>MAD cohort 3</arm_group_label>
    <arm_group_label>MAD cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI: 18 - 32 kg/m2, inclusive

          -  Female subjects: must be of non-childbearing potential (either surgically sterilized
             or at least 1 year post-menopausal (amenorrhea duration of 12 months)

          -  Ability and willingness to abstain from alcohol, methylxanthine-containing beverages
             or food (coffee, tea, cola, chocolate, &quot;power drinks&quot;) and grapefruit (juice) from 48
             h prior to entry in the clinical research center until discharge

          -  Medical history without major pathology

          -  Resting supine blood pressure and pulse rate showing no clinically relevant deviations
             as judged by the MI

          -  Computerised (12-lead) ECG recording without signs of clinically relevant pathology or
             showing no clinically relevant deviations as judged by the MI

          -  All values for hematology and for clinical chemistry tests of blood and urine within
             the normal range or showing no clinically relevant deviations as judged by the MI

          -  Willingness to sign the written Informed Consent Form (ICF)

        Exclusion Criteria:

          -  Evidence of clinically relevant pathology

          -  Mental handicap

          -  History of relevant drug and/or food allergies

          -  Regular/routine treatment with non-topical medications within 30 days prior to drug
             administration

          -  Use of tobacco products (less than 60 days prior to drug administration)

          -  History of alcohol abuse or drug addiction (including soft drugs like cannabis
             products)

          -  Use of concomitant medication (including over the counter medication, health
             supplements, multivitamins and vitamin C, vitamin and omega-3 supplements, and herbal
             remedies such as St. John's Wort extract) must have been stopped at least 14 days
             prior to the first dose. The use of a limited amount of acetaminophen (paracetamol) is
             permitted on discretion of the MI.

          -  Participation in a drug study within 60 days prior to drug administration.
             Participation in more than 3 other drug studies in the 10 months preceding the start
             of this study.

          -  Donation of more than 100 mL of blood within 60 days prior to drug administration.
             Donation of more than 1.5 litres of blood in the 10 months preceding the start of this
             study.

          -  Positive screen on drugs of abuse (opiates, methadone, cocaine, amphetamines,
             cannabinoids), barbiturates, benzodiazepines, tricyclic antidepressants and alcohol

          -  Intake of more than 24 units of alcohol per week (one unit of alcohol equals
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

          -  Positive screen on HBsAg

          -  Positive screen on anti HCV

          -  Positive screen on anti HIV 1/2

          -  Illness within 5 days prior to (the first) drug administration

          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of
             thorax and bony skeleton (excluding spinal column)), during work or during
             participation in a medical trial in the previous year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renger Tiessen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Per Gjorstrup, MD PhD Chief Medical Officier</name_title>
    <organization>Resolvyx</organization>
  </responsible_party>
  <keyword>Resolvins</keyword>
  <keyword>RvE1</keyword>
  <keyword>Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

